Clinical Analysis Of Polymorphous Bronchioloalveolar Carcinoma In Sixty-Four Cases

ObjectiveBronchioloalveolar carcinoma(BAC)have a tendency to increase in recent years.Due to the complexity of the diversity in clinical manifestation and chest imaging,clinical easily misdiagnosed.This study collect clinical data to summarize characteristics of BAC clinical symptoms,radiological characteristics,and the effect of the different therapies,so as to improve clinician awareness of the disease and the level of diagnosis and treatment.MethodsWe retrospectively analyzed the clinical data of 64 BAC patients who were admitted to the department of respiratory and thoracic surgery in the Second Affiliated Hospital Of Chongqing Medical University from January, 2005 to May,2011,including gender,age,smoking history and smoking index,main clinical symptoms,complications,chest radiological characteristics,misdiagnosis,treatment,all the patients were followed up to December,2013,compare the survival between the different treatments.ResultsIn the enrolled cases,the ratio of male to female is 1.28:1,average age is 61 years old,10 patients’s smoking index more than 400,clinical features of BAC are cough,expectoration, chest pain,chest imaging manifestations varied,the most common type is like pneumonia,32 patients were misdiagnosis as other disease,the longest misdiagnosis time is 9 years,64 patients were divided into three groups,treated with operation,chemotherapy,chemotherapy combine EGFR-TKIs,the median overall survival in operation is 34 months,in chemotherapy is 12 months,chemotherapy combine EGFR-TKIs is 32.6 months,through statistical analysis of chemotherapy combined with EGFR-TKIs group had a significant survival advantage than chemotherapy,but there were no significant difference between operation and combined treatment group.ConclusionsCharacteristics clinical symptoms of BAC is cough a lot of white foamy sputum,but majority of the patient observed with cough as the main clinical manifestations,chest radiological diversity,when we observed the ground glass opacity or lesions of pneumonia do not absorb after anti-inflammatory therapy,should think the possible of BAC,those who unable to tolerate chemotherapy or have underlying disease should choose EGFR-TKIs as a first-line treatment.